2024 annual financial data
TScan Therapeutics 2024 Operating margin
Direct answer
Operating margin was -4,787.68%.
Operating income was -134,821,000 USD and net income was -127,499,000 USD.
Operating cash flow was -110,822,000 USD.
Get free TScan Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 2,816,000 USD
- Operating income
- -134,821,000 USD
- Net income
- -127,499,000 USD
- Operating cash flow
- -110,822,000 USD